Home > Insider Trading > Filing (0001493152-22-007206)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1642380	Oncocyte Corp	OCX	In Vitro & In Vivo Diagnostic Substances (2835)	271041563

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807104	Gisela Paulsen	15 Cushing Irvine CA 92618	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, No Par Value	Acquisiton	2022-03-17	16,500	$1.20	16,500	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Acquisiton	2022-03-15	125,000	$0.00	125,000	$1.15
Common Stock	Option to Purchase Common Stock	Acquisiton	2022-03-15	125,000	$0.00	125,000	$1.15

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,000		2032-03-15	No	4	A	Direct
125,000		2032-03-15	No	4	A	Direct

Footnotes

The price of $1.198 per share represents a weighted average of prices ranging from $1.180 to $1.200 per share. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price
25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.